Advancements in Cell and Gene Therapy Manufacturing: Automation, Cost Reduction, and Scalability Revolutionize Patient Access

August 9, 2026

Bioprocessing Summit Europe International

Overview

The cell and gene therapy (CGT) manufacturing sector faces significant operational challenges, including high costs and scalability constraints, particularly due to raw material variability and contamination risks from manual processes. To address this, the industry is rapidly transitioning towards robust closed and automated platforms. Smart manufacturing leveraging AI and machine learning, alongside the adoption of new analytical techniques for process and product characterization, is enabling cost reductions, accelerating patient delivery, improving consistency and reproducibility for iPSC therapies, and enhancing quality control and supply chain efficiency. These advancements hold the potential to democratize CGT access and fundamentally transform patient care.

In Depth

Key Findings

The cell and gene therapy (CGT) manufacturing industry is accelerating its transition towards robust closed and automated platforms to address critical operational challenges, notably high costs and scalability limitations. This strategy aims to overcome issues such as raw material variability, supply chain constraints, and contamination risks associated with manual processes, ensuring both cost-efficiency and regulatory compliance.

Technical and Clinical Details

Innovative strategies, tools, and methodologies are being adopted across both autologous and allogeneic therapy manufacturing. Process automation, machine learning (ML), and artificial intelligence (AI)-driven smart manufacturing are considered key to enhancing manufacturing efficiency and quality control. For example, the use of digital shadows to predict CAR T-cell concentration contributes to process monitoring and optimization. In the production of induced pluripotent stem cell (iPSC) therapies, technological advancements focused on improving process consistency and reproducibility are highly prioritized. New analytical techniques are being leveraged for process and product characterization, ensuring product quality and safety. These technologies are indispensable for reducing contamination risks, maintaining product comparability, and meeting stringent manufacturing control standards required by regulatory authorities.

Background and Industry Context

Commercialization of CGT products continues to face unique challenges related to scale-up, material sourcing, parallelization, automation, and quality control. The FDA projects 10 to 20 new CGT approvals annually by 2025, necessitating dramatic improvements in manufacturing capacity and reductions in the Cost of Goods Sold (COGS). Current manufacturing environments often rely on manual processes, which are primary contributors to contamination risks, batch-to-batch inconsistency, and high costs. Therefore, implementing closed systems and automation is viewed as an essential solution for standardizing production, mitigating risks, and ultimately accelerating product delivery to patients.

Strategic Significance and Outlook

The advancements in automation, AI/ML, and digitalization are poised to profoundly transform the future of CGT manufacturing. These technologies promise to enhance manufacturing efficiency, scalability, and quality, thereby democratizing access to CGT and fundamentally altering the landscape of patient care. Regulatory bodies are also increasing their focus on manufacturing controls and product comparability, with approaches like non-viral production gaining attention as simpler and safer gene editing pathways. Moving forward, further reductions in manufacturing costs and improvements in global supply chain and logistics will be critical determinants for the widespread adoption of CGT.

Source: https://www.bioprocessingeurope.com/cell-therapy-manufacturing

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.